NasdaqGM:TMDX

Stock Analysis Report

Executive Summary

Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has TransMedics Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.0%

TMDX

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

TMDX

9.7%

US Medical Equipment

0.7%

US Market

No trading data on TMDX.

No trading data on TMDX.


Share holder returns

TMDXIndustryMarket
7 Day3.0%1.2%-0.6%
30 Day6.2%3.5%4.9%
90 Day-11.7%3.2%1.7%
1 Yearn/a10.6%9.7%3.0%0.7%
3 Yearn/a70.6%65.4%44.8%35.4%
5 Yearn/a139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is TransMedics Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TransMedics Group undervalued based on future cash flows and its price relative to the stock market?

6%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

TransMedics Group's share price is below the future cash flow value, but not at a moderate discount (< 20%).

TransMedics Group's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

TransMedics Group is loss making, we can't compare its value to the US Medical Equipment industry average.

TransMedics Group is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for TransMedics Group, we can't assess if its growth is good value.


Price Based on Value of Assets

TransMedics Group is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is TransMedics Group expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

68.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

TransMedics Group's revenue is expected to grow significantly at over 20% yearly.

TransMedics Group's earnings are expected to grow significantly at over 20% yearly.

TransMedics Group's revenue growth is expected to exceed the United States of America market average.

TransMedics Group's earnings growth is expected to exceed the United States of America market average.

TransMedics Group's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if TransMedics Group will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has TransMedics Group performed over the past 5 years?

-40.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

TransMedics Group does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare TransMedics Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare TransMedics Group's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if TransMedics Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if TransMedics Group has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if TransMedics Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is TransMedics Group's financial position?


Financial Position Analysis

TransMedics Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

TransMedics Group's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

TransMedics Group's level of debt (47.6%) compared to net worth is high (greater than 40%).

Unable to establish if TransMedics Group's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

TransMedics Group has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if TransMedics Group has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is TransMedics Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate TransMedics Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate TransMedics Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as TransMedics Group has not reported any payouts.

Unable to verify if TransMedics Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as TransMedics Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of TransMedics Group's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Waleed Hassanein (51yo)

21.1yrs

Tenure

US$524,000

Compensation

Dr. Waleed H. Hassanein, M.D. is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He Founded TransMedics, Inc. in August 1998 and h ...


CEO Compensation Analysis

Waleed's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Waleed to compare compensation growth.


Management Age and Tenure

2.8yrs

Average Tenure

51yo

Average Age

The tenure for the TransMedics Group management team is about average.


Board Age and Tenure

15.7yrs

Average Tenure

61yo

Average Age

The average tenure for the TransMedics Group board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$533,32806 May 19
Edwin Kania
EntityIndividual
Role
Member of the Board of Directors
Director
Shares33,333
Max PriceUS$16.00
BuyUS$136,00006 May 19
Edward Basile
EntityIndividual
Shares8,500
Max PriceUS$16.00

Ownership Breakdown


Management Team

  • Waleed Hassanein (51yo)

    Founder

    • Tenure: 21.1yrs
    • Compensation: US$524.00k
  • John Carey (55yo)

    Vice President of Operations

    • Tenure: 6.7yrs
  • Tamer Khayal (50yo)

    Chief Commercial Officer

    • Tenure: 0yrs
    • Compensation: US$415.80k
  • Stephen Gordon (51yo)

    CFO. Treasurer & Secretary

    • Tenure: 4.5yrs
    • Compensation: US$371.25k
  • Ike Okonkwo (48yo)

    Vice President of Finance & Accounting

    • Tenure: 0.5yrs
  • Brian Thomson (51yo)

    Vice President of Human Resources

    • Tenure: 1yrs
  • Mark Anderson

    Senior Director of Technology Development

    • Tenure: 0.7yrs

Board Members

  • Ed Kania (61yo)

    Director

    • Tenure: 15.7yrs
  • Jim Tobin (74yo)

    Chairman

    • Tenure: 8.7yrs
  • Waleed Hassanein (51yo)

    Founder

    • Tenure: 21.1yrs
    • Compensation: US$524.00k
  • Edward Zavala

    Member of Advisory Board

    • Tenure: 0yrs
  • Gayle Winters

    Member of Advisory Board

    • Tenure: 0yrs
  • Ryszard Smolenski

    Member of Advisory Board

    • Tenure: 0yrs
  • Bruce Rosengard

    Member of Advisory Board

    • Tenure: 0yrs
  • Scott Solomon

    Member of Advisory Board

    • Tenure: 0yrs
  • Bob Kormos

    Member of Advisory Board

    • Tenure: 0yrs
  • Valluvan Jeevanandam

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

TransMedics Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TransMedics Group, Inc.
  • Ticker: TMDX
  • Exchange: NasdaqGM
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$522.273m
  • Shares outstanding: 21.12m
  • Website: https://www.transmedics.com

Number of Employees


Location

  • TransMedics Group, Inc.
  • 200 Minuteman Road
  • Suite 302
  • Andover
  • Massachusetts
  • 1810
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TMDXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2019

Biography

Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company off ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:22
End of Day Share Price2019/09/20 00:00
Earnings2019/06/29
Annual Earnings2018/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.